NIH Begins Clinical Trial to Treat COVID-19

May 15, 2020 by Mandy Qualls

Filed under COVID-19 for Employers, COVID-19 for the Workforce

Last modified May 18, 2020

According to a press release from the National Institutes of Health (NIH), the first participant enrolled today in San Diego, California for a clinical trial that has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from COVID-19. 

The Phase 2b trial will enroll approximately 2,000 adults across the United States. Study participants must have confirmed infection with SARS-CoV-2 and be experiencing fever, cough and/or shortness of breath. The press release also states that investigators anticipate many of those enrolled will be 60 years of age or older or have a comorbidity associated with developing serious complications from COVID-19, such as cardiovascular disease or diabetes.

Share this

Related Articles

                                Leave a Comment